Seeking Alpha

ChemoCentryx rallies on CCX168 data

  • ChemoCentryx (CCXI) is out with top-line data from a Phase 2 study of CCX168 in ANCA-associated AARV.
  • In short, the company says the results demonstrate "that CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AARV patients, without compromising efficacy or safety during a 12-week treatment period."
  • The data (at 12 weeks): CCX168 plus CYC plus low-dose steroids, renal remission 75%, urinary MCP-1, -72%; CCX168 plus CYC plus no steroids, renal remission 63%, urinary MCP-1, -52%; SOC, renal remission 44%, urinary MCP-1, -37%. (PR)
  • CCXI +6.5% AH
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)